Clinical Trial Results:
Pharmacokinetics and metabolic activation of capecitabine when given concomitantly with oxaliplatin and the monoclonal antibody cetuximab
Summary
|
|
EudraCT number |
2011-002921-23 |
Trial protocol |
AT |
Global end of trial date |
27 Mar 2014
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
27 Jul 2016
|
First version publication date |
27 Jul 2016
|
Other versions |
Trial Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
|
|||
Trial identification
|
|||
Sponsor protocol code |
AGMT-Capecet_PK
|
||
Additional study identifiers
|
|||
ISRCTN number |
- | ||
US NCT number |
NCT01579357 | ||
WHO universal trial number (UTN) |
- | ||
Sponsors
|
|||
Sponsor organisation name |
AGMT
|
||
Sponsor organisation address |
Gentzgasse 60/20, Vienna, Austria, 1180
|
||
Public contact |
Daniela Wolkersdorfer, AGMT, 0043 6626404411, d.wolkersdorfer@agmt.at
|
||
Scientific contact |
Richard Greil, AGMT, 0043 5725525801, r.greil@salk.at
|
||
Paediatric regulatory details
|
|||
Is trial part of an agreed paediatric investigation plan (PIP) |
No
|
||
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial? |
No
|
||
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial? |
No
|
||
Results analysis stage
|
|||
Analysis stage |
Final
|
||
Date of interim/final analysis |
27 Mar 2014
|
||
Is this the analysis of the primary completion data? |
No
|
||
Global end of trial reached? |
Yes
|
||
Global end of trial date |
27 Mar 2014
|
||
Was the trial ended prematurely? |
No
|
||
General information about the trial
|
|||
Main objective of the trial |
The objective of this pharmacokinetic study is to exclude a possible influence of CETUX on the plasma disposition and metabolic activation of Capecitabine (CCB) and when this regimen is given combined with Oxaliplatin (OxPt).
|
||
Protection of trial subjects |
Pretreatment before Cetuximab and chemotherapie was recommended. No additional investigating products, anti-tumoural drugs or drugs interacting with the EGFreceptor were allowed. Hematopoietic growth factors such as G-CSF could be used to treat neutropenia but should not be used prophylactically. Safety was monitored by reporting of clinical adverse events.
|
||
Background therapy |
Capecitabine 1000mg/m² bid q7d week 1,2,4,5,7 and 8 Oxaliplatin 130mg/m² iv day 1 week 7 | ||
Evidence for comparator |
- | ||
Actual start date of recruitment |
06 Mar 2012
|
||
Long term follow-up planned |
No
|
||
Independent data monitoring committee (IDMC) involvement? |
No
|
||
Population of trial subjects
|
|||
Number of subjects enrolled per country |
|||
Country: Number of subjects enrolled |
Austria: 28
|
||
Worldwide total number of subjects |
28
|
||
EEA total number of subjects |
28
|
||
Number of subjects enrolled per age group |
|||
In utero |
0
|
||
Preterm newborn - gestational age < 37 wk |
0
|
||
Newborns (0-27 days) |
0
|
||
Infants and toddlers (28 days-23 months) |
0
|
||
Children (2-11 years) |
0
|
||
Adolescents (12-17 years) |
0
|
||
Adults (18-64 years) |
15
|
||
From 65 to 84 years |
13
|
||
85 years and over |
0
|
|
||||||||||||||||||||||
Recruitment
|
||||||||||||||||||||||
Recruitment details |
Between 06-Mar-2012 and 07-Jan-2014 28 patients were enrolled at two sites in Austria. | |||||||||||||||||||||
Pre-assignment
|
||||||||||||||||||||||
Screening details |
Patients with histologically confirmed K-ras wild-type adenocarcinoma of the colon or rectum without previous chemotherapy for metastatic disease were screened for this study. Subjects who did not complete the entire study due to withdrawal or discontinuation for any reason were replaced. | |||||||||||||||||||||
Period 1
|
||||||||||||||||||||||
Period 1 title |
Overall trial (overall period)
|
|||||||||||||||||||||
Is this the baseline period? |
Yes | |||||||||||||||||||||
Allocation method |
Randomised - controlled
|
|||||||||||||||||||||
Blinding used |
Not blinded | |||||||||||||||||||||
Arms
|
||||||||||||||||||||||
Are arms mutually exclusive |
Yes
|
|||||||||||||||||||||
Arm title
|
Arm A | |||||||||||||||||||||
Arm description |
Capecitabine in weeks 1, 2, 4, 5, 7 and 8 Cetuximab in weeks 3 to 9 Oxaliplatin in week 7 | |||||||||||||||||||||
Arm type |
Experimental | |||||||||||||||||||||
Investigational medicinal product name |
Cetuximab
|
|||||||||||||||||||||
Investigational medicinal product code |
||||||||||||||||||||||
Other name |
||||||||||||||||||||||
Pharmaceutical forms |
Solution for infusion
|
|||||||||||||||||||||
Routes of administration |
Intravenous use
|
|||||||||||||||||||||
Dosage and administration details |
Cetuximab 400mg/m² (loading dose) or 250mg/m² iv day 1 week 3 to 9
|
|||||||||||||||||||||
Arm title
|
Arm B | |||||||||||||||||||||
Arm description |
Capecitabine in weeks 1, 2, 4, 5, 7 and 8 Cetuximab in weeks 1, 8 and 9 Oxaliplatin in week 7 | |||||||||||||||||||||
Arm type |
Experimental | |||||||||||||||||||||
Investigational medicinal product name |
Cetuximab
|
|||||||||||||||||||||
Investigational medicinal product code |
||||||||||||||||||||||
Other name |
||||||||||||||||||||||
Pharmaceutical forms |
Solution for infusion
|
|||||||||||||||||||||
Routes of administration |
Intravenous use
|
|||||||||||||||||||||
Dosage and administration details |
Cetuximab 400mg/m² (loading dose) or 250mg/m² iv day 1 week 1, 8 and 9
|
|||||||||||||||||||||
|
|
||||||||||||||||||||||||||||||||||
Baseline characteristics reporting groups
|
||||||||||||||||||||||||||||||||||
Reporting group title |
Overall trial
|
|||||||||||||||||||||||||||||||||
Reporting group description |
- | |||||||||||||||||||||||||||||||||
|
|
|||
End points reporting groups
|
|||
Reporting group title |
Arm A
|
||
Reporting group description |
Capecitabine in weeks 1, 2, 4, 5, 7 and 8 Cetuximab in weeks 3 to 9 Oxaliplatin in week 7 | ||
Reporting group title |
Arm B
|
||
Reporting group description |
Capecitabine in weeks 1, 2, 4, 5, 7 and 8 Cetuximab in weeks 1, 8 and 9 Oxaliplatin in week 7 |
|
||||||||||
End point title |
A metabolic activation of CCB modulated by co-administered CETUX [1] | |||||||||
End point description |
The objective of this pharmacokinetic study is to exclude a possible influence of CETUX on the plasma disposition and metabolic activation of CCB and when this regimen is given combined with OxPt.
|
|||||||||
End point type |
Primary
|
|||||||||
End point timeframe |
9 weeks of study treatment per patient
|
|||||||||
Notes [1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point. Justification: No data available up to this date |
||||||||||
|
||||||||||
Notes [2] - No data available up to this date [3] - No data available up to this date |
||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Adverse events information
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Timeframe for reporting adverse events |
All (serious) adverse events occurring during study treatment were collected until 28 days after the end of study treatment.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Assessment type |
Systematic | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dictionary used for adverse event reporting
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dictionary name |
MedDRA | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dictionary version |
17.0
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting groups
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Overall trial
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
- | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Frequency threshold for reporting non-serious adverse events: 0% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
|||
Substantial protocol amendments (globally) |
|||
Were there any global substantial amendments to the protocol? No | |||
Interruptions (globally) |
|||
Were there any global interruptions to the trial? No | |||
Limitations and caveats |
|||
Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data. | |||
None reported |